DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cytarabine (Cytarabine) - Platelet Count Decreased - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Platelet Count Decreased ()

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include platelet count decreased. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of    Next >>

Possible Cytarabine side effects in female

Reported by a physician from United Kingdom on 2012-08-10

Patient: female

Reactions: Neutropenic Sepsis, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 40mg every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-21

Ofatumumab
    Dosage: 1000mg cyclic
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-20

Cisplatin
    Dosage: 100mgm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-21

Cytarabine
    Dosage: 4gm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-22



Possible Cytarabine side effects in female

Reported by a physician from United Kingdom on 2012-08-07

Patient: female

Reactions: Sepsis, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ofatumumab
    Dosage: 1000mg cyclic
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-20

Cisplatin
    Dosage: 100mgm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-21

Cytarabine
    Dosage: 4gm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-22

Dexamethasone
    Dosage: 40mg every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-21



Possible Cytarabine side effects in 59 year old female

Reported by a physician from United States on 2012-07-18

Patient: 59 year old female

Reactions: Respiratory Failure, Platelet Count Decreased, Febrile Neutropenia, Upper Gastrointestinal Haemorrhage, Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-02-11

Cytarabine
    Dosage: 1920 mg, cyclic
    Start date: 2012-05-16
    End date: 2012-05-16

Sprycel
    Dosage: 600 mg, cyclic
    Administration route: Oral
    Start date: 2012-05-16
    End date: 2012-05-26

Sprycel
    Dosage: unk
    Administration route: Oral
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-02-11



Possible Cytarabine side effects in female

Reported by a physician from United Kingdom on 2012-07-16

Patient: female

Reactions: Sepsis, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ofatumumab
    Dosage: 1000mg cyclic
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-20

Cisplatin
    Dosage: 100mgm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-21

Dexamethasone
    Dosage: 40mg every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-21

Cytarabine
    Dosage: 4gm2 every 3 weeks
    Indication: Diffuse Large B-Cell Lymphoma Recurrent
    Start date: 2012-06-22



Possible Cytarabine side effects in 38 year old female

Reported by a physician from United States on 2012-06-25

Patient: 38 year old female

Reactions: White Blood Cell Count Decreased, Anaemia, Febrile Neutropenia, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Methotrexate Sodium
    Dosage: 1880 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13

Leucovorin Calcium
    Dosage: 125 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13

Cytarabine
    Dosage: 5640 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13

Methylprednisolone
    Dosage: 300 mg, unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13

Sprycel
    Dosage: 980 mg, unk
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-04-13



Possible Cytarabine side effects in 5 year old female

Reported by a physician from United States on 2012-05-29

Patient: 5 year old female, weighing 21.4 kg (47.1 pounds)

Reactions: White Blood Cell Count Decreased, Bacterial Infection, Febrile Neutropenia, Endocarditis, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mitoxantrone
    Indication: Acute Promyelocytic Leukaemia
    Start date: 2011-12-19

Trisenox
    Indication: Acute Promyelocytic Leukaemia
    Start date: 2012-04-13

Cytarabine
    Indication: Acute Promyelocytic Leukaemia
    Start date: 2011-12-19

Cytarabine
    Dosage: high dose
    Start date: 2012-04-25

Tretinoin
    Indication: Acute Promyelocytic Leukaemia
    Start date: 2011-12-19



Possible Cytarabine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-05-14

Patient: female, weighing 43.8 kg (96.4 pounds)

Reactions: Disinhibition, Hypoaesthesia Oral, Protrusion Tongue, Balance Disorder, Oxygen Saturation Decreased, Grimacing, Nausea, Blepharospasm, Abnormal Behaviour, Body Temperature Decreased, Haemoglobin Decreased, Affect Lability, Heart Rate Increased, Platelet Count Decreased, Memory Impairment, Inappropriate Affect, Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Hydrocortisone
    Dosage: 45 mg
    End date: 2012-04-25

Daunorubicin Hydrochloride
    Dosage: 140 mg
    End date: 2012-03-28

Mercaptopurine
    Dosage: 1150 mg
    End date: 2012-04-24

Vincristine Sulfate
    Dosage: 4 mg
    End date: 2012-05-03

Cytarabine
    Dosage: 1090 mg
    End date: 2012-04-25

PEG-L-Aspraginase (Pegasparagase, Oncospar)
    Dosage: 3375 iu
    End date: 2012-04-25

Methotrexate
    Dosage: 45 mg
    End date: 2012-04-25

Cyclophosphamide
    Dosage: 2800 mg
    End date: 2012-05-09



Possible Cytarabine side effects in male

Reported by a individual with unspecified qualification from United States on 2012-05-14

Patient: male, weighing 103.3 kg (227.3 pounds)

Reactions: Oral Mucosal Blistering, Anaemia, Rash Papular, Blood Blister, Headache, Haemolysis, Dysgeusia, Haemoglobin Decreased, Ecchymosis, Platelet Count Decreased, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytoxan
    Dosage: 4600 mg

Cytarabine
    Dosage: 2890 mg

Vincristine Sulfate
    Dosage: 4 mg

PEG-L -Asparaginase (K-H)
    Dosage: 5700 unit

Methotrexate
    Dosage: 60 mg

Mercaptopurine
    Dosage: 3900 mg



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from China on 2012-05-11

Patient:

Reactions: Hypersensitivity, Petechiae, Off Label Use, Neurotoxicity, Hepatotoxicity, Granulocytopenia, Bone Marrow Failure, White Blood Cell Count Decreased, Gastrointestinal Toxicity, Anaemia, Nephropathy Toxic, Urinary Tract Infection, Toxicity To Various Agents, Soft Tissue Infection, Sepsis, Platelet Count Decreased, Infection

Drug(s) suspected as cause:
Mesna
    Indication: Acute Myeloid Leukaemia

Epirubicin
    Indication: non-Hodgkin's Lymphoma

Epirubicin
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: non-Hodgkin's Lymphoma

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Vindesine
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Vindesine
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: non-Hodgkin's Lymphoma

Mesna
    Indication: non-Hodgkin's Lymphoma

Other drugs received by patient: Leucovorin Calcium



Possible Cytarabine side effects in

Reported by a health professional (non-physician/pharmacist) from China on 2012-05-10

Patient:

Reactions: Hypersensitivity, Neurotoxicity, Off Label Use, Hepatotoxicity, Granulocytopenia, Bone Marrow Failure, White Blood Cell Count Decreased, Gastrointestinal Toxicity, Nephropathy Toxic, Urinary Tract Infection, Anaemia, Soft Tissue Infection, Acute Lymphocytic Leukaemia, Sepsis, Platelet Count Decreased, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Mesna
    Indication: Acute Myeloid Leukaemia

Methotrexate
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Mesna
    Indication: non-Hodgkin's Lymphoma

Vindesine
    Indication: Acute Lymphocytic Leukaemia

Vindesine
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone TAB
    Indication: non-Hodgkin's Lymphoma

Dexamethasone TAB
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Leucovorin Calcium



Possible Cytarabine side effects in 18 year old male

Reported by a physician from United States on 2012-05-10

Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)

Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Pegaspargase
    Dosage: 2500 iu, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-25
    End date: 2012-03-02

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Vincristine
    Dosage: 2 mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Prednisone TAB
    Dosage: 50 mg, bid
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-04

Methotrexate
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia

Hydrocortisone
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia

Cytarabine
    Dosage: 70 mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24

Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-02-24



Possible Cytarabine side effects in 71 year old male

Reported by a physician from Japan on 2012-05-10

Patient: 71 year old male

Reactions: White Blood Cell Count Decreased, Interstitial Lung Disease, Anaemia, Platelet Count Decreased, Pleural Effusion

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Sprycel
    Dosage: 70 mg, 2x/day
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-22

Neupogen
    Indication: Acute Lymphocytic Leukaemia

Oncovin
    Indication: Acute Lymphocytic Leukaemia

Idarubicin HCL
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-08
    End date: 2012-02-15

Cytarabine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-08
    End date: 2012-02-15

Other drugs received by patient: Candesartan Cilexetil; Dexamethasone Sodium Phosphate; Fluconazole; Allopurinol; Polymyxin B Sulfate; Cotrim; Neutrogin



Possible Cytarabine side effects in male

Reported by a individual with unspecified qualification from United States on 2012-04-26

Patient: male, weighing 89.8 kg (197.6 pounds)

Reactions: White Blood Cell Count Decreased, Platelet Count Decreased, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine



Possible Cytarabine side effects in male

Reported by a physician from United States on 2012-04-17

Patient: male, weighing 91.7 kg (201.7 pounds)

Reactions: Pneumonia, Dyspnoea, Vocal Cord Paresis, Hypotension, Pulmonary Alveolar Haemorrhage, Scab, Laryngeal Oedema, Febrile Infection, Herpes Simplex, Platelet Count Decreased, Hypoxia, Tachypnoea

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 1470 mg
    End date: 2012-03-26

Daunorubicin HCL
    Dosage: 375 mg
    End date: 2012-03-22



Possible Cytarabine side effects in 18 year old male

Reported by a consumer/non-health professional from United States on 2012-04-13

Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)

Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: 2 mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Prednisone TAB
    Dosage: 50 mg, bid
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-04

Hydrocortisone
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia

Pegaspargase
    Dosage: 2500 iu, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-25
    End date: 2012-03-02

Cytarabine
    Dosage: 70 mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24

Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-02-24

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Methotrexate
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia



Possible Cytarabine side effects in male

Reported by a individual with unspecified qualification from United States on 2012-04-13

Patient: male, weighing 91.7 kg (201.7 pounds)

Reactions: Dyspnoea, Vocal Cord Paresis, Hypotension, Pulmonary Alveolar Haemorrhage, Pyrexia, Laryngeal Oedema, Herpes Simplex, Platelet Count Decreased, Hypoxia, Tachypnoea

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 1470 mg
    End date: 2012-03-26

Daunorubicin HCL
    Dosage: 375 mg
    End date: 2012-03-22



Possible Cytarabine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-04-05

Patient: female, weighing 53.6 kg (117.9 pounds)

Reactions: Abdominal Pain, Tachycardia, Faeces Discoloured, Haematemesis, Posterior Reversible Encephalopathy Syndrome, Enterocolitis, Nausea, Hepatic Steatosis, Convulsion, Cholelithiasis, Mallory-Weiss Syndrome, Bacteraemia, Platelet Count Decreased, Ammonia Increased, Neutropenia, Hypertension, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mercaptopurine
    Dosage: 2500 mg

Cyclophosphamide
    Dosage: 2900 mg

Cytarabine
    Dosage: 216 mg



Possible Cytarabine side effects in 65 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-05

Patient: 65 year old male, weighing 125.5 kg (276.1 pounds)

Reactions: White Blood Cell Count Decreased, Pulmonary Oedema, Platelet Count Decreased, Device Related Infection, Neutrophil Count Decreased, Rash Maculo-Papular, Cerebrovascular Accident, Pneumonitis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Idarubicin HCL
    Dosage: 12 milligram/sq. meter
    Start date: 2011-12-05
    End date: 2011-12-23

Cytarabine
    Dosage: 100 milligram/sq. meter
    Start date: 2012-02-17
    End date: 2012-02-25

Idarubicin HCL
    Dosage: 12 milligram/sq. meter
    Start date: 2012-02-17
    End date: 2012-02-22

Revlimid
    Dosage: 30 milligram
    Administration route: Oral
    Start date: 2012-02-17
    End date: 2012-02-24

Revlimid
    Dosage: 30 milligram
    Administration route: Oral
    Start date: 2011-12-05
    End date: 2011-12-23

Cytarabine
    Dosage: 100 milligram/sq. meter
    Start date: 2011-12-05
    End date: 2011-12-23

Other drugs received by patient: Neupogen



Possible Cytarabine side effects in 18 year old male

Reported by a physician from United States on 2012-04-03

Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)

Reactions: White Blood Cell Count Decreased, Abdominal Pain, Metabolic Acidosis, Clostridium Test Positive, Urine Output Decreased, Hypotension, Hyponatraemia, Capillary Leak Syndrome, Platelet Count Decreased, Septic Shock

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Oncaspar
    Dosage: 2500 iu;x1;iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Doxorubicin HCL
    Dosage: 60 mg/m**2;x1;iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-24
    End date: 2012-02-24

Velcade
    Dosage: 1.3 mg/m**2; qd; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Vincristine
    Dosage: 1.5 mg/m**2;qd;iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Prednisone TAB
    Dosage: 20 mg/m**2;qd;po
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-04

Cytarabine
    Dosage: 70 mg;x1;inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-02-24

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: inth
    Indication: Acute Lymphocytic Leukaemia



Possible Cytarabine side effects in female

Reported by a physician from United States on 2012-03-28

Patient: female, weighing 84.3 kg (185.5 pounds)

Reactions: Hyperglycaemia, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Daunorubicin HCL
    Dosage: 96 mg

Methylprednisolone
    Dosage: 1320 mg

Vincristine Sulfate
    Dosage: 2 mg

Cytarabine
    Dosage: 70 mg

Methotrexate
    Dosage: 15 mg

PEG-L-Asparaginase (K-H)
    Dosage: 48000 unit

Other drugs received by patient: Acetaminophen; Protonix; Alteplase; Bactrim; Docusate Sodium; Magnesium Sulfate; Zofran; Acyclovir; Morphine; Insulin / Lispro; Lorazepam; Odanesetron; Scopalamine; Biotene Mouth Rinse; Lantus; Lomotil; Allopurinol; Cefazolin; Diphenhydramine HCL; Micafungin; Ceftazidime; Vicodin; Zolpidem; Clotrimazole; Dextrose; Insulin / Glargine; Medroxyprogesterone; Nystatin; Potassium Chloride; Sodium Chloride



Possible Cytarabine side effects in 18 year old male

Reported by a consumer/non-health professional from United States on 2012-03-13

Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)

Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 60 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-02-24

Vincristine
    Dosage: 1.5 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Cytarabine
    Dosage: 70 mg, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24

Pegaspargase
    Dosage: 2500 iu, cyclic
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-02

Methotrexate
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia

Prednisone TAB
    Dosage: 20 mg/m2, cyclic
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-02-24
    End date: 2012-03-04

Hydrocortisone
    Dosage: unk
    Indication: B Precursor Type Acute Leukaemia



Possible Cytarabine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-03-13

Patient: female, weighing 53.6 kg (117.9 pounds)

Reactions: Dyspnoea, Tachycardia, Mental Status Changes, Hepatic Steatosis, Cholelithiasis, Mallory-Weiss Syndrome, Bacteraemia, Sepsis, Ammonia Increased, Platelet Count Decreased, Enterocolitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: 30 mg

PEG-L Asparaginase (K-H)
    Dosage: 3625 k

Mercaptopurine
    Dosage: 2500 mg

Cytarabine
    Dosage: 216 mg

Cyclophosphamide
    Dosage: 2900 mg

Vincristine Sulfate
    Dosage: 4 mg



Possible Cytarabine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-02-24

Patient: female, weighing 88.0 kg (193.6 pounds)

Reactions: Agitation, Blood Bilirubin Increased, Confusional State, Haemorrhage, Body Temperature Increased, Acidosis, Multi-Organ Failure, Haematocrit Decreased, Oxygen Saturation Decreased, Dyspnoea, Alanine Aminotransferase Increased, General Physical Health Deterioration, Haemoglobin Decreased, Aspartate Aminotransferase Increased, Platelet Count Decreased, Pulse Absent, Septic Shock, Staphylococcus Test Positive

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Daunorubicin HCL
    Dosage: 360 mg
    End date: 2012-02-10

Cytarabine
    Dosage: 1400 mg
    End date: 2012-02-04



Possible Cytarabine side effects in male

Reported by a physician from United States on 2012-02-23

Patient: male, weighing 21.5 kg (47.3 pounds)

Reactions: Bacillus Test Positive, Platelet Count Decreased, Headache, Pyrexia, Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 5400 mg
    End date: 2012-02-05

Mitoxantrone Hydrochloride
    Dosage: 18 mg
    End date: 2012-02-06

Tretinoin
    Dosage: 280 mg
    End date: 2012-02-16



Possible Cytarabine side effects in 18 year old male

Reported by a physician from United States on 2012-02-21

Patient: 18 year old male, weighing 72.0 kg (158.4 pounds)

Reactions: Respiratory Failure, Platelet Count Decreased, Herpes Zoster, Klebsiella Sepsis

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: ;x1; inth ;x1; inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-29

Methotrexate
    Dosage: ;x1; inth ;x1; inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-13
    End date: 2012-01-13

Prednisone TAB
    Dosage: 20 ug/ m**2; bid; po
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29

Vincristine
    Dosage: 1.5 mg/ m**2; qw; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2012-01-28

Velcade
    Dosage: 1.3 mg/m**2; qd; iv
    Indication: Acute Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-30

Cytarabine
    Dosage: ;x1; inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-29

Oncaspar
    Dosage: 2500 iu/m2; qw; im
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2012-01-28

Doxorubicin HCL
    Dosage: 60 mg/ m**2; qd; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-30

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29



Possible Cytarabine side effects in male

Reported by a physician from United States on 2012-02-08

Patient: male, weighing 103.9 kg (228.6 pounds)

Reactions: Thrombosis, Pain, Chills, Pyrexia, Erythema, Feeling Hot, Blindness Unilateral, Mass, Muscular Weakness, Staphylococcal Sepsis, Retinitis, Choroidal Effusion, Platelet Count Decreased, Abscess, Neutropenia, Choroidal Detachment

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Daunorubicin HCL
    End date: 2011-10-27

Cytarabine
    Dosage: 41220 mg
    End date: 2011-12-22



Possible Cytarabine side effects in male

Reported by a individual with unspecified qualification from United States on 2012-02-07

Patient: male, weighing 103.9 kg (228.6 pounds)

Reactions: Vitritis, Leukaemic Infiltration, Retinal Detachment, Chills, Pyrexia, Catheter Site Discharge, Myalgia, Malaise, Device Deployment Issue, Blindness Unilateral, Eye Abscess, Muscle Spasms, Renal Failure Acute, Exophthalmos, Cellulitis, Visual Field Defect, Mass, Staphylococcal Sepsis, Eye Pain, Choroidal Effusion, Joint Abscess, Conjunctival Haemorrhage, Arthritis Infective, Ocular Hyperaemia, Retinal Exudates, Purulence, Platelet Count Decreased, Neutropenia, Asthenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 41220 mg
    End date: 2011-12-22

Daunorubicin HCL
    End date: 2011-10-27



Possible Cytarabine side effects in 9 year old female

Reported by a physician from United States on 2012-01-30

Patient: 9 year old female, weighing 39.4 kg (86.7 pounds)

Reactions: Tachycardia, Pulmonary Embolism, Pyrexia, Constipation, Somnolence, Hypokalaemia, Partial Seizures, Sinusitis, Blepharospasm, Atrial Thrombosis, Hypotension, Cerebral Atrophy, Rash, Varicella Virus Test Positive, Tremor, Haemoglobin Decreased, Fungal Infection, Bacteraemia, Lacunar Infarction, Hypoalbuminaemia, Platelet Count Decreased, Neutropenia, Seizure Like Phenomena

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg, 3x/day, subuctaneous; 100 mg once, subcutaneous
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-07
    End date: 2011-06-10

Cytarabine
    Dosage: 100 mg, 3x/day, subuctaneous; 100 mg once, subcutaneous
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-13
    End date: 2011-06-16

Vincristine Sulfate
    Dosage: 2 mg, weekly, intravenous; 1.9 mg, single, intravenous
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-04-08
    End date: 2011-04-29

Vincristine Sulfate
    Dosage: 2 mg, weekly, intravenous; 1.9 mg, single, intravenous
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-20
    End date: 2011-06-20

*peg-Asparaginase (Asparaginase) Unknown
    Dosage: 3150 iu, single, intramuscular
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-20
    End date: 2011-06-20

Methotrexate
    Dosage: see image
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-06
    End date: 2011-06-06

Methotrexate
    Dosage: see image
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-13
    End date: 2011-06-13

Methotrexate
    Dosage: see image
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-05-06
    End date: 2011-05-06

Methotrexate
    Dosage: see image
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-20
    End date: 2011-06-20

Methotrexate
    Dosage: see image
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-04-15
    End date: 2011-04-15

Dalteparin Sodium
    Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
    Indication: Pulmonary Embolism
    Start date: 2011-05-13
    End date: 2011-06-26

Dalteparin Sodium
    Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
    Indication: Atrial Thrombosis
    Start date: 2011-05-13
    End date: 2011-06-26

Dalteparin Sodium
    Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
    Indication: Pulmonary Embolism
    Start date: 2011-06-27

Dalteparin Sodium
    Dosage: 5395 iu, 2x/day, subcutaneous; 5395 iu, 2x/day, subcutaneous
    Indication: Atrial Thrombosis
    Start date: 2011-06-27

Cyclophosphamide
    Dosage: 1300 mg single, intravenous; 100mg once, subcutaneous
    Start date: 2011-06-06
    End date: 2011-06-06

Mercaptopurine
    Dosage: 75 mg, once daily six days per week, oral; 100 mg, once per day on seventh day of week, oral
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-06
    End date: 2011-06-19

Mercaptopurine
    Dosage: 75 mg, once daily six days per week, oral; 100 mg, once per day on seventh day of week, oral
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2011-06-06
    End date: 2011-06-19

Other drugs received by patient: Zofran; Bactrim; Sodium Chloride 0.9%; Heparin; Ranitidine Hydrochloride; Emla; Acetaminophen



Possible Cytarabine side effects in

Reported by a individual with unspecified qualification from Germany on 2012-01-26

Patient:

Reactions: White Blood Cell Count Decreased, Pneumonia, Hyperbilirubinaemia, Dyspnoea, Febrile Neutropenia, Pancytopenia, Toxicity To Various Agents, Stem Cell Transplant, Mucosal Inflammation, Interstitial Lung Disease, Platelet Count Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Etoposide
    Dosage: days 4-7
    Indication: B-Cell Lymphoma

Mabthera
    Dosage: days 1 and 8
    Indication: B-Cell Lymphoma

Cytarabine
    Dosage: days 4-7
    Indication: B-Cell Lymphoma

Dexamethasone
    Dosage: days 1-10
    Administration route: Oral
    Indication: B-Cell Lymphoma

Melphalan Hydrochloride
    Dosage: day 3
    Indication: B-Cell Lymphoma

Carmustine
    Dosage: day 2
    Indication: B-Cell Lymphoma



Possible Cytarabine side effects in female

Reported by a physician from United States on 2011-11-17

Patient: female, weighing 67.6 kg (148.7 pounds)

Reactions: Abdominal Pain, Disseminated Intravascular Coagulation, Hepatic Failure, Gastrointestinal Necrosis, Caecitis, Haemodynamic Instability, Vaginal Haemorrhage, Adhesion, Haematoma, Renal Failure Acute, Neutropenic Colitis, Vomiting, General Physical Health Deterioration, Lung Disorder, Pericarditis, Sepsis, Gastrointestinal Disorder, Platelet Count Decreased, Multi-Organ Disorder

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 3680 mg
    End date: 2011-10-27

Daunorubicin HCL
    Dosage: 255 mg
    End date: 2011-10-18

Etoposide
    Dosage: 850 mg
    End date: 2011-10-18



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014